Fast molecular UTI testing, closer to the patient
Lodestar DX is a portable molecular UTI testing system designed for near-patient use by professional users. It detects six UTI-causing bacterial pathogens from a tiny drop of urine, providing sample-to-result in less than 40 minutes.
Because of its simplicity of use, weight, small footprint, and proven ability to accurately rule in or rule-out the presence of UTI-causing pathogens, Lodestar is suitable for a broad range of applications in primary and secondary healthcare settings.
From problem to practical product
The need is clear: faster diagnostic information, closer to the patient.
Llusern’s response is the Lodestar UTI testing system – a portable molecular testing system designed to support faster, better-informed treatment decisions in professional settings.
Key product points
Implementation GuideLess than 40 minutes
Small urine sample
No extraction step
Six bacterial targets
Portable analyser
Simple LED results
MDx designed for the real-world
Lodestar DX has been designed for real-world professional settings, where time, space and simplicity matter. The system packages molecular diagnostic capability into a compact, portable analyser that can be used beyond conventional laboratory environments.
Practical design features
- Small footprint: 140 mm x 200 mm x 90 mm
- Weight: 720 g
- Bluetooth and USB connectivity
- Simple LED result display
- No servicing required
- Designed for near-patient professional settings
Simple results for professional users
Lodestar DX presents results through simple LED indicators.
A red LED indicates a positive result. A green LED indicates a negative result.
If more than one bacterial tube is positive, this indicates a potential mixed infection.
This clear user experience supports faster interpretation of results.
UTI focused today.
Broader platform potential
Llusern’s first focus is rapid UTI testing. The wider opportunity is to make molecular testing for a portfolio of infectious diseases more accessible in healthcare settings where a fast treatment decisions impacts the patient pathway.
Lodestar DX creates a focused device-plus-consumables opportunity, with recurring test panel revenues and broader platform potential over time.
Designed for multiple professional settings
Lodestar DX was specifically developed to be used near to the patient so that intervention decisions can be made quickly and where a fast, accurate result has the biggest impact.
Testimonials
Lodestar DX represents an important step in making molecular UTI testing practical at the point where treatment decisions are made.
By bringing clearer diagnostic information closer to the patient, it can support faster, better-informed decisions in real-world professional settings.
As a spinal injury patient, new symptoms feel overwhelming. Lodestar gave me instant peace of mind. I drove two hours to Reading just to avoid the usual three day wait for culture results. It is brilliant.
For months, my NHS results came back as ‘mixed growth’ or ‘no significant growth’, which basically left me with no treatment plan and I felt fobbed off; it was such a waste of everyone’s time.
The Lodestar machine identified the specific three bacteria immediately. I wish I’d come here sooner; it’s the first time I’ve had a definitive answer and I’ve felt empowered.
News & Insights
- Awards
- Clinical Studies
- Appointments
Llusern bags a hat-trick at ICS 2026.
Two abstracts published in The Journal of Urology.
Llusern announces changes to Exec team and new NED
Explore the commercial potential behind Lodestar DX
The Lodestar UTI testing system gives Llusern a defined first product for a recurring diagnostic need, with relevance across human and veterinary settings.
To learn more about the opportunity behind the product, explore the commercial potential or speak to the Llusern team.
